Clinical Trials Browser

Phase 2/3 × NIH × Ramucirumab × Clear all

NCT06203600 2026-03-17

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Phase 2/3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus